New drug APAC aims to prevent blood clots in leg artery patients
NCT ID NCT07352800
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called APAC, which is designed to prevent blood clots in people with blocked leg arteries. The trial includes 42 adults with peripheral arterial disease or chronic limb-threatening ischemia. Researchers will check if APAC is safe and well-tolerated, and compare different doses to standard care or a placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
APAC (a heparin-like drug to prevent blood clots)
What this could lead to
If successful, this could lead to a new treatment option to prevent blood clots and improve outcomes for patients with severe leg artery disease.
What could go wrong
This is an early Phase 2 trial with only 42 participants, so results may not apply to everyone. The drug may cause side effects or not work better than current treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERIPHERAL ARTERIAL OCCLUSIVE DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Helsinki University Hospital
RECRUITINGHelsinki, 00290, Finland
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Tampere University Hospital
RECRUITINGTampere, Finland
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Turku University Hospital
RECRUITINGTurku, Finland
Contact Phone: •••-•••-•••• Email: •••••@•••••